Roche announced a significant phase 3 trial win for its selective estrogen receptor degrader (SERD) in a broad breast cancer population, outperforming standard-of-care treatments. This advancement addresses unmet clinical needs in hormone receptor-positive breast cancer, potentially setting a new standard. Details remain sparse on subgroup analyses and regulatory pathways, but the positive data marks a key step in Roche’s oncology portfolio expansion.